Does EU MDR compliance extend a US device maker’s products liability to EU claims?

On this site "MDR" almost everywhere means Medical Device Reporting under 21 CFR Part 803, the FDA obligation to report device-associated deaths, serious injuries, and malfunctions. This question is about something different: the EU Medical Device Regulation, Regulation (EU) 2017/745, which governs placing a device on the European market.

The two are unrelated, and conflating them is a common and expensive source of confusion when a US manufacturer starts reading European contract language.

Article 10(16) requires manufacturers to have measures in place to provide sufficient financial coverage for potential liability under the applicable product liability regime, proportionate to the risk class, the type of device, and the size of the enterprise. It does not name a limit, a form, or a carrier. That vagueness is deliberate and it means the obligation is judged against your specific risk profile rather than a published number.

Anyone quoting you a single required EU limit is describing a market convention or a specific contract demand, not the text of the regulation. Treat stated figures as commercial requirements to be verified against the actual agreement.

A manufacturer outside the EU must appoint an EU Authorised Representative. Under Article 11 that representative carries defined regulatory duties, and it can be held jointly and severally liable alongside the manufacturer for a defective device.

That exposure is why AR agreements routinely require indemnification, additional insured status, and evidence of products liability that responds in the EU. Your AR is not being difficult. They are managing a liability the regulation places on them, and their contract is where your coverage territory problem becomes contractual rather than theoretical.

Directive (EU) 2024/2853 replaces the long-standing product liability regime. Member states are required to transpose it by 9 December 2026. Two changes matter for life sciences: the definition of a product expressly covers software, which pulls software as a medical device and device-embedded algorithms squarely into strict product liability, and the routes of recourse against importers and authorised representatives are strengthened when the manufacturer sits outside the EU.

For a US manufacturer, that combination means EU claimants have clearer paths to a defendant inside the EU, and that defendant has a contract with you. Reviewing AR and importer agreements against the new regime before transposition is the practical action, not after.

Separate the two questions. Compliance asks whether you hold coverage proportionate to your risk, which is largely a documentation and limits exercise. Response asks whether the policy you hold pays when the claim is brought in an EU forum, which is the coverage territory question addressed in the international sales entry.

Both usually need to be solved together before CE marking translates into shipped volume, because the AR agreement and the distribution agreement typically land at the same moment.